Navigation Links
ETHEX Corporation Issues Voluntary Nationwide Recall of Prescription Prenatal and Iron Supplements to Wholesale Level
Date:2/3/2009

ST. LOUIS, Feb. 3 /PRNewswire/ -- ETHEX Corporation, a subsidiary of KV Pharmaceutical Company (NYSE: KVa/KVb), is issuing a voluntary nationwide recall of the products identified below (all lots within their expiration dates) at a wholesale level. The Company is taking this action as a precautionary measure, because the products may have been manufactured under conditions that did not sufficiently comply with current Good Manufacturing Practice (cGMP).

Patients who may have these products in their possession should continue to take them in accordance with their prescriptions, as the risk of suddenly stopping needed medications may place patients at risk. Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using these products, or to obtain replacement medications or prescriptions.

Products Recalled to the Wholesale/Distributor Level:

Prescription Prenatal Vitamin Products:

    Advanced NatalCare(R) Tablets               Advanced-RF NatalCare(R) Tablets
    Cal-Nate(TM) Tablets                         CareNatal(TM) DHA Tablets
    ComBgen Tablets                           ComBiRx(TM)Tablets
    NataCaps Capsules                         NatalCare Gloss Tablets
    NatalCare PIC Tablets                     NatalCare PIC Forte Tablets
    NatalCare Plus Tablets                    NatalCare Rx Tablets
    NatalCare Three Tablets                   NataTab FA Tablets
    NataTab RX Tablets                        NutriNate(R) Chewable Tablets
    NutriSpire(TM) Tablets                       Prenatal MR 90 FE Tablets
    Prenatal MTR w/Selinium Tablets           Prenatal Rx 1 Tablets
    Prenatal Z, Advanced Formula Tablets      Ultra NatalCare Tablets

Prescription Iron Supplement Products:

    Anemagen Caplets                          Anemagen Forte Caplets
    Conison(TM) Capsules                         Fe-Tinic(TM) 150 Forte Capsules

Any wholesaler inquiries related to this action should be addressed to ETHEX Customer Service at 1-800-748-1472, faxed to ETHEX Customer Service at 314-646-3788, or e-mailed to customer-service@ethex.com. Representatives are available Monday through Friday, 8 am to 5 pm CST.

ETHEX Corporation has initiated recall notifications to wholesalers nationwide who received any inventory of the recalled products, with instructions for returning the recalled products.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA). At this time, the Company is unable to determine when distribution of these products will resume.

Patients with questions about the recall should call the telephone number above, or contact their healthcare providers. Any adverse reactions experienced with the use of these products should also be reported to FDA's MedWatch Program by phone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, by mail at MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at www.fda.gov/medwatch.

The recall announcement is posted on www.kvpharmaceutical.com.

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology distinguished products through ETHEX Corporation, a national leader in generic pharmaceuticals, and Ther-Rx Corporation, its branded drug subsidiary.


'/>"/>
SOURCE ETHEX Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ETHEX Corporation Issues Voluntary Nationwide Recall
2. ETHEX Corporation Initiated Nationwide Voluntary Recalls of Specific Lots of Five Generic Products Due to the Potential for Oversized Tablets
3. ETHEX Corporation Voluntarily Recalls Three Lots of Dextroamphetamine Sulfate 5mg Tablets Due to the Potential for Oversized Tablets
4. ETHEX Corporation Voluntarily Recalls a Single Lot of Morphine Sulfate 60 mg Extended Release Tablets Due to the Potential for Oversized Tablets
5. ALSIUS CORPORATION PREPARED TO INVALIDATE ZOLL TEMPERATURE MANAGEMENT PATENTS
6. Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2009
7. Techne Corporation Declares Dividend
8. DURECT Corporation Invites You to Join Its Fourth Quarter 2008 Earnings Conference Call
9. Digirad Corporation Sells Northern California Service Hubs
10. Torchmark Corporation Announces Fourth Quarter 2008 Earnings Release and Conference Call
11. NutriSystem Expands Voluntary United States Recall of Peanut Butter Granola Breakfast Bar to Include Canada Due to Possible Peanut Corporation of America (PCA) Contamination and Potential Health Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, ... University of Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) ... program, developed in association with efforts by the American College of Surgeons, U.S. ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... laboratory instruments are critical to ensuring high-quality results and maintaining GMP and USP ... of Laboratory Instruments in accordance with GMP requirements " these requirements are explained. ...
(Date:3/28/2017)... ... 28, 2017 , ... With less than 10,000 dermatologists in the United States ... be limited while the desire to conquer breakouts and eliminate skincare stress is widespread. ... customer online, today released its inaugural survey on the State of Acne in America. ...
(Date:3/28/2017)... ... , ... Columbus OH. Dr. Justin Harper, Founder of Juvly Aesthetics in Ohio ... country to sit on the 2017 National Advisory Board for Allergan’s Facial Aesthetics National ... helped propel the clinic from a small start-up to number 78 in the country ...
(Date:3/28/2017)... ... March 28, 2017 , ... Public relations pros work hard to ... of business channels. , While many results are clear, much of PR is hard ... , When it comes to measurement, firms should always take an all-inclusive approach that ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... Mass. , March 28, 2017 ... company developing innovative therapeutics that address significant unmet ... a patent from the Japan Patent Office (JPO) ... connective tissue growth factor (CTGF) for the treatment ... limited to skin fibrosis and proliferative retinopathy (Japanese ...
(Date:3/28/2017)... , March 28, 2017 ... research with Cambridge ... Consortium   The Milner Therapeutics Institute today announces ... Elysium Health has committed significant investment for collaborative projects with ... next four years. This is the first major research investment ...
(Date:3/27/2017)... TEL-AVIV, Israel , March 27, 2017 /PRNewswire/ ... TASE: THXBY), a specialty clinical-stage pharmaceutical company specializing in the ... of its public offering in the ... Shares (ADSs), each ADS representing 40 ordinary shares ... per ADS. In addition, Therapix has granted the ...
Breaking Medicine Technology: